tirzepatide patent challenge FDA confirms shortage is still over, gives compounders a grace period Top drug patent expirations in

The FDAs removal of tirzepatide from its Drug Shortages Database in April 2025 fundamentally altered the prescribing landscape

NICE guidance (NG28) recommends GLP-1 receptor agonists for type 2 diabetes in specific clinical circumstances, typically when metformin and other treatments have not achieved glycaemic targets

In those cases, coverage may continue to be handled through the beneficiarys Part D plan, depending on the medication, diagnosis, and plan formulary

Store 2-8 C (short-term) or 20 C (long-term) per validated stability/institutional practice

BMR is influenced by age, sex, height, weight, and body composition